Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents
Keywords:
Attention deficit hyperactivity disorder, central nervous system, gamma‐Aminobutyric acidAbstract
These days, psychoactive substances—such as cognitive enhancers, which can improve or restore brain function—as well as "recreational" drugs, like novel psychoactive substances (NPS), are still, and in some cases, are becoming, more widely available. There are advantages and disadvantages to using psychoactive drugs. While new medications to treat cognitive symptoms in neuropsychiatric or neurodegenerative disorders may be very helpful for many patient groups, the ease with which recreational NPS is becoming more widely available and the growing prevalence of cognitive enhancers among healthy individuals means that managing psychoactive substances effectively will become more and more important. A class of medications known as immunosuppressants works by preventing or lessening the body's immune response. The majority of these drugs work by making the body less likely to reject an organ transplant. Immunosuppressive drugs are required in solid organ transplantation in order to maintain organ rejection, manage late-stage immunosuppression, or initiate early-stage immunosuppression. This advancement is mostly due to the development of new drugs and advancements in post-transplant immunosuppressive protocols. These medications do, however, also raise the risk of infection, cancer, and certain negative side effects that are unique to each agent in patients, especially in pregnant women and those who are having fertility problems. The coronavirus disease, a contentious issue, has improved the effectiveness of immunosuppressive medications but still need further research. Many immunosuppressive protocols are used at transplant facilities worldwide; nevertheless, each patient may need a customized immunosuppression regimen to balance the benefits and potential risks of treatment, thereby removing the chance of recurrence of their initial disease.
References
1. d'Angelo LC, Savulich G, Sahakian BJ. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. Br J Pharmacol. 2017 Oct;174(19):3257-3267. doi: 10.1111/bph.13813.
2. Hussain Y, Khan H. Immunosuppressive Drugs. Encyclopedia of Infection and Immunity. 2022:726–40. doi: 10.1016/B978-0-12-818731-9.00068-9.
3. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The concise guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors. Br J Pharmacol 172: 5744–5869.
4. Alexander SPH, Peters JA, Kelly E, Marrion N, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Ligand‐gated ion channels. Br J Pharmacol 172: 5870–5903.
5. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The concise guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
6. Brühl AB, Sahakian BJ (2016). Drugs, games, and devices for enhancing cognition: implications for work and society. Ann N Y Acad Sci 1369: 195–217.
7. Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJA, Parsons LH (2016). Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17: 293–306.
8. Adams D.M., et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2) doi: 10.1542/peds.2015-3257.
9. Ahmed A.R., et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. International Immunopharmacology. 2016;34:25–31. doi: 10.1016/j.intimp.2016.02.013.
10. Akbari M., et al. Topical tacrolimus as an adjunct to conventional therapy for stromal herpetic keratitis: A randomized clinical trial. Journal of Ophthalmic & Vision Research. 2019;14(4):400. doi: 10.18502/jovr.v14i4.5437.
11. Akioka K., et al. Transplantation Proceedings. Elsevier; 2017. Hyperuricemia and acute renal failure in renal transplant recipients treated with high-dose mizoribine.
12. Kim J.H., et al. Increased exposure of tacrolimus by co-administered mycophenolate mofetil: Population pharmacokinetic analysis in healthy volunteers. Scientific Reports. 2018;8(1):1–9. doi: 10.1038/s41598-018-20071-3.
13. Lin R., et al. Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. Basic & Clinical Pharmacology & Toxicology. 2021;128(3):482–492. doi: 10.1111/bcpt.13530.
14. Mallat S.G., et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor–based regimen versus a CNI-based regimen: A systematic review and meta-analysis of randomized, controlled trials. Clinical Journal of the American Society of Nephrology. 2017;12(8):1321–1336. doi: 10.2215/CJN.13221216.
15. Sharma, Y., Arora, M. & Bala, K. The potential of immunomodulators in shaping the future of healthcare. Discov Med 1, 37 (2024). https://doi.org/10.1007/s44337-024-00029-3
16. Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14:1055.
17. Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8:886.
18. Planat-Benard V, Varin A, Casteilla L. MSCs and Inflammatory Cells Crosstalk in Regenerative Medicine: Concerted Actions for Optimized Resolution Driven by Energy Metabolism. Front Immunol. 2021;12.
19. Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int. 2018. https://doi.org/10.1155/2018/3057624.
20. Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7: e2062.
21. Strzelec M, Detka J, Mieszczak P, Sobocińska MK, Majka M. Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol. 2023;14:1127704.
